HealthPhoto: Business StandardDCGI Approves Dr Reddy's Zytorvi for Esophageal Cancer
Dr Reddy's Laboratories has received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma (ESCC) in India. The drug, combined with cisplatin and paclitaxel, is approved for unresectable, recurrent, or metastatic ESCC in adults. This is Zytorvi's second indication after nasopharyngeal carcinoma. ESCC accounts for 80% of esophageal cancers in India. Approval is based on Phase 3 JUPITER-06 trial showing a 42% risk reduction in disease or death.
Business Standard·




